Azitra (NYSEAMERICAN:AZTR) Trading Down 4.7% – Here’s What Happened

Posted by Alanna Baker on Dec 13th, 2025

Shares of Azitra, Inc. (NYSEAMERICAN:AZTR – Get Free Report) dropped 4.7% during trading on Thursday . The stock traded as low as $0.3593 and last traded at $0.3650. Approximately 275,800 shares changed hands during trading, a decline of 20% from the average daily volume of 343,099 shares. The stock had previously closed at $0.3830.

Wall Street Analysts Forecast Growth

Separately, Maxim Group decreased their price objective on shares of Azitra from $13.32 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, September 24th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $4.00.

Check Out Our Latest Analysis on Azitra

Azitra Stock Down 5.6%

The firm’s 50 day simple moving average is $0.48 and its 200-day simple moving average is $1.01.

Azitra (NYSEAMERICAN:AZTR – Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.12. Equities research analysts forecast that Azitra, Inc. will post -2.78 EPS for the current fiscal year.

Institutional Investors Weigh In On Azitra

A hedge fund recently raised its stake in Azitra stock. National Bank of Canada FI increased its stake in shares of Azitra, Inc. (NYSEAMERICAN:AZTR – Free Report) by 175.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 110,000 shares of the company’s stock after buying an additional 70,000 shares during the quarter. National Bank of Canada FI owned about 0.88% of Azitra worth $34,000 at the end of the most recent quarter. 11.16% of the stock is currently owned by institutional investors and hedge funds.

About Azitra

(Get Free Report)

Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.